Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Businessman,Using,A,Mobile,Phone,To,Check,Stock,Market,Data,

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.

The company’s lead drug candidate, BPL-003, is under development for treatment-resistant depression.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.